Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib versus prednisone in previously treated metastatic castration-resistant prostate cancer
NL-OMON37289Phase 3Recruiting
- Sponsor
- PPD
- Start
- Mar 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) and bone metastases comparing Cabozantinib arm with Prednisone arm (2 arms). Primary endpoint: Overall survival. Started Mar 2013; status: recruiting.
02
Drugs
cabozantinibprednisone
03
Conditions
prostate cancer (PCa)bone metastases
Beyond the preview
Go deeper on NL-OMON37289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37289.